273 related articles for article (PubMed ID: 19591808)
1. Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges.
Williams M
Biochem Pharmacol; 2009 Dec; 78(11):1360-5. PubMed ID: 19591808
[TBL] [Abstract][Full Text] [Related]
2. The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine.
Smith SM; Uslaner JM; Yao L; Mullins CM; Surles NO; Huszar SL; McNaughton CH; Pascarella DM; Kandebo M; Hinchliffe RM; Sparey T; Brandon NJ; Jones B; Venkatraman S; Young MB; Sachs N; Jacobson MA; Hutson PH
J Pharmacol Exp Ther; 2009 Mar; 328(3):921-30. PubMed ID: 19088300
[TBL] [Abstract][Full Text] [Related]
3. Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.
Strick CA; Li C; Scott L; Harvey B; Hajós M; Steyn SJ; Piotrowski MA; James LC; Downs JT; Rago B; Becker SL; El-Kattan A; Xu Y; Ganong AH; Tingley FD; Ramirez AD; Seymour PA; Guanowsky V; Majchrzak MJ; Fox CB; Schmidt CJ; Duplantier AJ
Neuropharmacology; 2011; 61(5-6):1001-15. PubMed ID: 21763704
[TBL] [Abstract][Full Text] [Related]
4. Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia.
Williams M
Curr Opin Investig Drugs; 2003 Jan; 4(1):31-6. PubMed ID: 12625025
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties.
Adage T; Trillat AC; Quattropani A; Perrin D; Cavarec L; Shaw J; Guerassimenko O; Giachetti C; Gréco B; Chumakov I; Halazy S; Roach A; Zaratin P
Eur Neuropsychopharmacol; 2008 Mar; 18(3):200-14. PubMed ID: 17681761
[TBL] [Abstract][Full Text] [Related]
6. Comments on 'The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia'.
Hashimoto K
J Psychopharmacol; 2010 Jul; 24(7):1133-4. PubMed ID: 19939869
[No Abstract] [Full Text] [Related]
7. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia.
Boks MP; Rietkerk T; van de Beek MH; Sommer IE; de Koning TJ; Kahn RS
Eur Neuropsychopharmacol; 2007 Sep; 17(9):567-72. PubMed ID: 17250995
[TBL] [Abstract][Full Text] [Related]
8. Is rat an appropriate animal model to study the involvement of D-serine catabolism in schizophrenia? Insights from characterization of D-amino acid oxidase.
Frattini LF; Piubelli L; Sacchi S; Molla G; Pollegioni L
FEBS J; 2011 Nov; 278(22):4362-73. PubMed ID: 21981077
[TBL] [Abstract][Full Text] [Related]
9. Drug discovery strategies and the preclinical development of D-amino-acid oxidase inhibitors as antipsychotic therapies.
Szilágyi B; Ferenczy GG; Keserű GM
Expert Opin Drug Discov; 2018 Oct; 13(10):973-982. PubMed ID: 30220232
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine.
Hashimoto K; Fujita Y; Horio M; Kunitachi S; Iyo M; Ferraris D; Tsukamoto T
Biol Psychiatry; 2009 Jun; 65(12):1103-6. PubMed ID: 19217074
[TBL] [Abstract][Full Text] [Related]
11. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
Yang CR; Svensson KA
Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
[TBL] [Abstract][Full Text] [Related]
12. Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.
Sershen H; Hashim A; Dunlop DS; Suckow RF; Cooper TB; Javitt DC
Neurochem Res; 2016 Feb; 41(1-2):398-408. PubMed ID: 26857796
[TBL] [Abstract][Full Text] [Related]
13. The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia.
Abou El-Magd RM; Park HK; Kawazoe T; Iwana S; Ono K; Chung SP; Miyano M; Yorita K; Sakai T; Fukui K
J Psychopharmacol; 2010 Jul; 24(7):1055-67. PubMed ID: 19329549
[TBL] [Abstract][Full Text] [Related]
14. Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia.
Madeira C; Freitas ME; Vargas-Lopes C; Wolosker H; Panizzutti R
Schizophr Res; 2008 Apr; 101(1-3):76-83. PubMed ID: 18378121
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia.
Ferraris DV; Tsukamoto T
Curr Pharm Des; 2011; 17(2):103-11. PubMed ID: 21361869
[TBL] [Abstract][Full Text] [Related]
16. Characterization of human D-amino acid oxidase.
Molla G; Sacchi S; Bernasconi M; Pilone MS; Fukui K; Polegioni L
FEBS Lett; 2006 Apr; 580(9):2358-64. PubMed ID: 16616139
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of D-amino acid oxidase inhibitors.
Ferraris D; Duvall B; Ko YS; Thomas AG; Rojas C; Majer P; Hashimoto K; Tsukamoto T
J Med Chem; 2008 Jun; 51(12):3357-9. PubMed ID: 18507366
[TBL] [Abstract][Full Text] [Related]
18. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
Large CH
J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
[TBL] [Abstract][Full Text] [Related]
20. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
Javitt DC
Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
